Population Life-course exposure to health effects model (PLETHEM): An R package for PBPK modeling
暂无分享,去创建一个
Harvey J. Clewell | Patrick D. McMullen | Miyoung Yoon | Marjory Moreau | Alina Efremenko | Salil N. Pendse | C. Eric Hack | Pankajini Mallick | Michael W. Dzierlenga | Chantel I. Nicolas | H. Clewell | P. McMullen | M. Yoon | M. Dzierlenga | Marjory Moreau | S. Pendse | A. Efremenko | Pankajini Mallick | C. Hack
[1] A. Rostami-Hodjegan,et al. Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter‐system extrapolation factors , 2011, Biopharmaceutics & drug disposition.
[2] Harvey J Clewell,et al. Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans , 2019, Toxicological sciences : an official journal of the Society of Toxicology.
[3] W. T. Berge,et al. A generic, cross-chemical predictive PBTK model with multiple entry routes running as application in MS Excel; design of the model and comparison of predictions with experimental results. , 2011, The Annals of occupational hygiene.
[4] Jerry L. Campbell,et al. Quantitative interpretation of human biomonitoring data. , 2008, Toxicology and applied pharmacology.
[5] Bas J Blaauboer,et al. Evaluation of simple in vitro to in vivo extrapolation approaches for environmental compounds. , 2014, Toxicology in vitro : an international journal published in association with BIBRA.
[6] J W Fisher,et al. In vitro to in vivo extrapolation for trichloroethylene metabolism in humans. , 1998, Toxicology and applied pharmacology.
[7] Melvin E. Andersen,et al. Incorporating High-Throughput Exposure Predictions With Dosimetry-Adjusted In Vitro Bioactivity to Inform Chemical Toxicity Testing , 2015, Toxicological sciences : an official journal of the Society of Toxicology.
[8] Harvey J Clewell,et al. Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.
[9] W. T. Berge,et al. A simple dermal absorption model: derivation and application. , 2009 .
[10] Hugh A Barton,et al. Developmental expression of aldehyde dehydrogenase in rat: a comparison of liver and lung development. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.
[11] G. Tucker,et al. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.
[12] D. Henschler,et al. Metabolism of trichloroethylene in man , 2004, Archives of Toxicology.
[13] Harvey J Clewell,et al. Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results , 2012, Critical reviews in toxicology.
[14] Bhagwat Prasad,et al. Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants , 2017, Drug Metabolism and Disposition.
[15] David M. Reif,et al. High-throughput models for exposure-based chemical prioritization in the ExpoCast project. , 2013, Environmental science & technology.
[16] Kannan Krishnan,et al. Physiologically-based pharmacokinetic (PBPK) models in toxicity testing and risk assessment. , 2012, Advances in experimental medicine and biology.
[17] Harvey J. Clewell,et al. Addressing Early Life Sensitivity Using Physiologically Based Pharmacokinetic Modeling and In Vitro to In Vivo Extrapolation , 2016, Toxicological research.
[18] Ethan Dmitrovsky,et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. , 1992 .
[19] H J Clewell,et al. A physiologically based pharmacokinetic model for retinoic acid and its metabolites. , 1997, Journal of the American Academy of Dermatology.
[20] Aleksandra Galetin,et al. Methods for predicting in vivo pharmacokinetics using data from in vitro assays. , 2008, Current drug metabolism.
[21] Harvey J. Clewell,et al. Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.
[22] A. Parkinson,et al. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. , 1997, Archives of biochemistry and biophysics.
[23] Daniel Vallero,et al. SHEDS-HT: an integrated probabilistic exposure model for prioritizing exposures to chemicals with near-field and dietary sources. , 2014, Environmental science & technology.
[24] Gerald T Ankley,et al. Computational toxicology: framework, partnerships, and program development. September 29-30, 2003, Research Triangle Park, North Carolina. , 2005, Reproductive toxicology.
[25] Nina Isoherranen,et al. Physiologically Based Pharmacokinetic Model of All-trans-Retinoic Acid with Application to Cancer Populations and Drug Interactions , 2017, The Journal of Pharmacology and Experimental Therapeutics.
[26] Jill Barber,et al. Expression of Hepatic Drug-Metabolizing Cytochrome P450 Enzymes and Their Intercorrelations: A Meta-Analysis , 2014, Drug Metabolism and Disposition.
[27] H J Clewell,et al. Comparison of cancer risk estimates for vinyl chloride using animal and human data with a PBPK model. , 2001, The Science of the total environment.
[28] Imran Shah,et al. Toxicokinetic Triage for Environmental Chemicals. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.
[29] Robert G. Pearce,et al. httk: R Package for High-Throughput Toxicokinetics. , 2017, Journal of statistical software.
[30] J. Lipscomb,et al. Covariation of Human Microsomal Protein Per Gram of Liver with Age: Absence of Influence of Operator and Sample Storage May Justify Interlaboratory Data Pooling , 2008, Drug Metabolism and Disposition.
[31] Harvey J Clewell,et al. Development and specification of physiologically based pharmacokinetic models for use in risk assessment. , 2008, Regulatory toxicology and pharmacology : RTP.
[32] W A Ritschel,et al. First-pass effect of coumarin in man. , 1979, International journal of clinical pharmacology and biopharmacy.